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S ubarachnoid hemorrhage (SAH) because of the rupture of an intracranial aneurysm (IA) occurs in 16 000 to 17 000 persons in the United States annually, over 40% die within 30 days. 1, 2 There is evidence that aneurysmal SAH has a genetic contribution. First degree relatives of an SAH patient have 2× to 6× greater frequency of an SAH compared with age-matched controls. [3] [4] [5] [6] First and second degree relatives of a patient with SAH or IA also have a greater risk of an unruptured IA (8.7%-13.9% ), compared with the general population (1%). [7] [8] [9] These data support a genetic contribution but could also be because of common lifestyle-related risk factors.
Genome-wide association studies identified and replicated significant associations at chromosome 4q31.23 (EDNRA), 5q31.3, 6q24.2, 8q12.1 (SOX17), 9p21.3 (CDKN2A/ CDKN2B/CDKN2BAS), 10q24.32 (CNNM2), 12q22, 13q13.1 (KL/STARD13), 18q11.2 (RBBP8), and 20p12.1. [10] [11] [12] [13] [14] [15] We used a case-control design to identify additional loci associated with IA in a large sample of European ancestry. IA cases were enriched for a positive family history of IA, which may increase the contribution of genetic factors. Two independent replication samples were examined to confirm the most promising findings in the discovery sample.
Subjects and Methods

Discovery Sample
The discovery sample involved 2617 white IA cases and 2548 white controls identified through different studies. Some of these samples were reported as part of a previous analysis. 12 IA cases were ascertained through 5 studies and controls through 5 studies. All studies obtained appropriate institutional ethics approvals (Materials in the online-only Data Supplement).
Genotyping and Quality Review
The discovery sample, with the exception of the Atherosclerosis Risk in Communities (ARIC) samples, was genotyped on the Affymetric Axiom array. The ARIC samples were genotyped on the Affymetric single nucleotide polymorphism (SNP) array 6.0. All released Axiom genotypes underwent a common quality review pipeline that included identification of sample duplicates, related individuals, and sex discrepancies. Before performing imputation, SNPs were excluded if there were (1) improper mapping to Genome Reference Consortium GRCh37, (2) a minor allele frequency <0.03, (3) SNP genotype call rate <95%, or (4) Hardy-Weinberg Equilibrium P<10 −4 in controls. Minor allele frequency and call rates were calculated by combining all Axiom array data. From the 597 320 SNPs on the Axiom array, 464 632 were retained after this quality review. The ARIC samples genotyped on the Affymetric SNP array 6.0 underwent the same quality review as the Axiom genotypes. From the 793 799 autosome SNPs on the Affymetric SNP array 6.0 that were provided by ARIC after their initial data review, a total of 626 645 were retained (Materials in the online-only Data Supplement).
Principal component analysis was performed using the SNPs genotyped on both the Axiom and Affymetric SNP array 6.0 platforms. Analyses were performed using Eigenstrat 16 using data from 11 HapMap phase III populations. To ensure that the discovery sample included only white subjects, all samples clustering outside the Utah residents of northern and western European ancestry and Toscans in Italy samples were excluded from further analysis. (Materials in the onlineonly Data Supplement; Figure I in the online-only Data Supplement).
Imputation and Statistical Analysis
Imputation was performed for all autosomes using IMPUTE2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html). All samples genotyped on the Axiom array that passed quality review (n=4060) were imputed together using the 1000Genomes haplotypes (n=1092) as the phased reference panel. Only variants with >1 minor copy across all 1000Genome populations were imputed. Original genotypes were not overwritten. ARIC samples that passed quality review (n=1132) were imputed separately using the same reference panel.
All ARIC samples genotyped on the Affymetrix SNP array 6.0 were controls, whereas all cases and the remaining controls were genotyped on the Axiom array. Therefore, extensive and detailed quality review was performed to ensure that spurious association was not detected based on platform effects. SNPs imputed in all data sets were not included in the analysis sample; only SNPs genotyped on at least one of the arrays (1 195 878 SNPs) were considered for inclusion in the analysis. We used the approach described by Sinnott and Kraft 17 which implements an aggressive filtering approach to remove SNPs having the potential for systematic platform differences (Materials in the online-only Data Supplement). The final data set retained 672 210 autosome SNPs for analysis.
The genotyped and imputed SNPs were tested for association with IA susceptibility using a logistic regression model. No additional covariates such as principal components for ancestry were necessary. Analysis was performed using the SNPTEST v2 software using an additive model of SNP effect. Imputed genotypes were encoded in the logistic model as the expected allele count. 18 For autosomal SNPs, all samples were analyzed together. For chromosome X, only SNPs that were on the Axiom array were included because the ARIC study samples only had genotypes for autosomal SNPs. Using the same quality control as above, 13 071 chromosome X SNPs were used. Genomic control was applied to correct for inflation (initial lambda λ =1.104; after genomic control, λ =1.0). Between the autosomes and X chromosome SNPs, the data set included 685 281 SNPs for the association analysis. We applied a Bonferroni correction to obtain the appropriate genome-wide threshold for significance (0.05/685 281=P<7.3×10 −8 ).
To test whether there might be more than one risk variant in a particular gene or gene region contributing to the association, conditional analyses were performed. A logistic regression model was used to include the genotype at the most significant SNP from the metaanalysis and to test for association with other SNPs in the region.
Replication and Meta-Analysis
Two independent case-control cohorts were used as replication samples. The first was a Dutch case-control sample. Patients with IA (n=786) admitted to the Utrecht University Medical Center (in The Netherlands) between 1997 and 2007 were included. This included both patients with ruptured and unruptured IA (Materials in the online-only Data Supplement). Controls were 3110 Dutch subjects recruited as part of the Nijmegen Biomedical Study and the Nijmegen Bladder Cancer Study. 19, 20 The second replication cohort was a case-control Finnish sample. The patients with IA (n=851), included both ruptured and unruptured IA, treated at the Helsinki and Kuopio University Hospitals (Materials in the online-only Data Supplement). Controls were 2317 
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Finnish individuals from 3 samples (Materials in the online-only Data Supplement): (1) Anonymous Finnish patients at the same hospitals as Finnish cases who gave blood samples for unrelated causes in consecutive days, (2) the Helsinki Birth Cohort Study (HBCS), 21 and (3) The Health 2000 cohort. 22, 23 The replication cohorts were genotyped on the Illumina CNV370-duo chips (Illumina Inc., San Diego, CA), and results were previously reported. 10, 15 Extensive quality control was performed in both subject and SNP data. Imputation was also performed in these samples (Materials in the online-only Data Supplement). The final Replication Samples included 717 Dutch cases, 3004 Dutch controls, 799 Finnish cases, and 2317 Finnish controls.
Replication was performed initially by reviewing results in each of the replication studies for the SNP on chromosome 7 that was found to be significantly associated with IA in the discovery sample. Replication was defined as P≤0.01 in either of the replication samples, with the direction of the SNP effect the same as in the Discovery Sample.
Subsequently, meta-analysis was performed in the chromosome 7 region by combining individual SNP results from the discovery sample and the replication sample. METAL 24 was used using an inversevariance weighting scheme. We evaluated results to identify findings meeting genome-wide significance criteria.
Results
Discovery Sample
The final sample included 2617 IA cases and 2548 controls (Tables 1 and 2 ). The cases across the studies had similar age of onset and all had a preponderance of females. The controls across the studies also had a similar age at the time of recruitment.
The most significant genome-wide results included SNPs in CDKN2BAS, also known as ANRIL (rs10733376; P=4.07×10 −12 ; odds ratio=1.34; 95% confidence interval: 1.23-1.45) on chromosome 9 (Figures 1 and 2A) previously associated with IA, as well as with other phenotypes. [12] [13] [14] [15] An SNP on chromosome 7 also met genome-wide significance (rs10230207; P=4.14×10 −8 ; Figures 1 and 2B ). This SNP is in an intergenic region 3′ of TWISTNB, MIR3146, and TMEM196 and near SNPs previously associated with ischemic stroke and large vessel occlusive ischemic subtype. 25 On chromosome 5, rs9687972 also reached genome-wide significance; however, no other SNPs in the same region provided similar evidence of association. This SNP was genotyped in the Axiom samples and imputed in the ARIC samples. The imputation information metric is 0.966, which indicates a good imputation; however, the genotype call rate in the Axiom samples was 95.5%, just above our threshold of 95%. The minor allele frequencies are 0.130 (in ARIC controls) and 0.115 (in Axiom controls; P value is 0.12, just above our threshold of 0.1). Therefore, this finding is likely a false-positive association.
On chromosome 7, imputed SNPs were analyzed to evaluate further the evidence of association. As expected, the imputed SNPs in high linkage disequilibrium (LD) with the most significant SNPs initially analyzed further supported the association with IA. The 3 neighboring regions on chromosome 7 which were examined ( Figure 2C) were independent of each other, suggesting that there might be independent evidence of association to IA susceptibility factors within this chromosomal region. Conditional analysis was performed and as expected, based on the lack of LD between the primary region and the 2 more distant regions, conditioning on the most significant SNP (rs10230207) did not significantly reduce the evidence of association in the other regions. However, none of these other regions on chromosome 7 attained genome-wide criteria, and therefore these results remained tentative.
Results did not exceed the genome-wide threshold in any other chromosomal region. In the chromosomal regions nominated by previous studies, P<0.01 was attained with the key SNPs nominated at chromosomes 4q31.23 and 8q12.1. In addition, although top SNPs previously reported on chromosomes 13q13.1 and 18q11.2 were not available in our sample, SNPs in LD with these SNPs attained P<0.01 ( Figure II in the online-only Data Supplement).
Replication Sample
Two independent replication samples were analyzed for evidence of association the SNPs on chromosome 7 identified in the discovery sample. The sample demographics are in Tables 3 and 4 .
Initially, only the single SNP (rs10230207) which had attained genome-wide evidence of association in the discovery sample was tested for association. When analyzing this SNP, the Dutch sample provided replication (P=0.01), whereas the Finnish sample failed to do so (P=0.25). Subsequently, metaanalysis was performed across the discovery sample and the 2 replication samples (Table 5) .
Discussion
We detected genome-wide evidence of association to a novel region on chromosome 7. The evidence of association was replicated in an independent Dutch sample with the same SNP (rs10230207) and in the same direction of effect. This region failed to show replication in the Finnish cohort, although the direction of effect was the same as in the other 2 samples and may be because of the different genetic architecture of the Finnish population. In addition, the incidence of SAH is higher in Finland compared with most other parts of the world, 26 suggesting that unique genetic factors may segregate in the Finnish population. Another possible explanation is that the size of the replication samples did not have sufficient power to replicate the association. Of note, the association on chromosome 9 with ANRIL has been replicated across many European populations, including the Finns. 13 The region on chromosome 7 identified in this study was associated with other stroke phenotypes in previous genomewide association studies. Matarín et al 25 reported association to chromosome 7p21.1 for ischemic stroke, although the finding did not meet genome-wide significance. Support for the association of ischemic stroke to this region was also found in a Han Chinese sample. 27 Large vessel stroke was associated with SNPs in HDAC9 on chromosome 7p21.1 28 ≈600 kb away from the initial reports for the more general ischemic stroke phenotype. Two other genes, TWIST1 and FERD3L, downstream of HDAC9 could not be excluded as underlying the association. Interestingly, unlike the earlier reports from Matarin and Ding, the SNPs in this region were not associated Our genome-wide significant association is closest to the finding by Matarin. There is LD between our top SNP (rs10230207) and theirs (r 2 =0.921). In our study, SNPs in and around HDAC9 did not attain genome-wide significance, but they provided modest evidence of association (P=10 -6 ; Table 5 ) that was independent of the association with rs10230207. The Dutch and Finnish sample did not have significant evidence of linkage with the SNPs in and around HDAC9. We also did not find extensive LD (r 2 =0.117) between our top SNP in this region and the SNP reported by the International Stroke Genetics Consortium (rs11984041). We performed a similar comparison with the METASTROKE association. We had modest evidence of association with the SNPs in the METASTROKE-associated region (P<10 -5 ); however, our most significant SNP was not in LD with the SNP identified in the METASTROKE study (rs2107595).
Our results along with those of other stroke consortium suggest that this region on chromosome 7 is associated with both IA and large vessel ischemic stroke subtype. Combined with our observation, one could speculate that IA, a disease of large intracranial arteries, and ischemic stroke because of large artery disease may share similar gene pathways and overlapping pathophysiology. Interestingly, the strongest genome-wide association studies evidence for IA to this point is for the region on chromosome 9p21.3, which has also been linked to large vessel ischemic stroke, myocardial infarction, and aortic aneurysm. Thus, genetic risk factors for large vessel vasculopathy may lead to different phenotypes depending on coexisting risk factors such as smoking, hypertension, hyperlipidemia, and other genetic risk factors.
A recent meta-analysis combined results from 61 candidate gene and genome-wide association studies and used association analysis to identify genes contributing to IA susceptibility. 30 The overall number of samples was 32 887 IA cases and 83 683 controls. The strongest evidence of association was on chromosome 9 in CDKN2B, chromosome 8 near SOX17, and chromosome 4 near EDNRA. These results were influenced by the available data, which typically did not include results for all SNPs, making it difficult to detect association to SNPs that were not identified in the initial report. In addition, by including candidate gene papers, the amount of available data was also limited, reducing the ability to detect novel associations in regions that have not yet been studied in the context of IA.
In summary, we identified and replicated in one sample a novel association with IA on chromosome 7 in a region previously reported to be associated with stroke. The associated region is near, although not in LD with HDAC9, which has been associated with large vessel stroke. Studies to replicate this association in additional cohorts of European or other ancestry are necessary and may suggest some overlapping pathogenesis across stroke types and would provide important new insights into the causes and potential targets for stroke prevention. 
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Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS):
Caucasian cases and controls identified from other studies, including those from the Australasian Cooperative Research on Subarachnoid hemorrhage Study (ACROSS), which was a prospective, population-based, case-control study of SAH undertaken in three cities in Australia and one city in New Zealand during the mid-1990s. 2 ACROSS included incidence cases of SAH secondary to documented or presumed ruptured IA who were frequency-matched (by sex, 10-year age strata, and city of residence) to controls selected from electoral rolls in each city. Detailed information about key exposures, such as smoking, hypertension, family history of stroke/IA, was obtained by standardized interviews with subjects (or proxies) and where possible, blood samples were obtained for storage and future DNA extraction. Samples from a total of 135 cases and 168 controls were available for genotyping in Discovery Sample 2. This study was approved by the institutional review committees at 10 sites. This sample has been has been included in a previous report. 
